Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Additional Listing

6 Jan 2014 16:33

RNS Number : 0136X
Epistem Holdings plc
06 January 2014
 



 

6th January, 2014

Epistem Holdings Plc

Additional Listing

Epistem (AIM: EHP) announces that 10,000 new ordinary shares of 1.5 pence each (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the Epistem Holdings Plc EMI Share Option Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 10th January, 2014 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following the admission to trading of the New Ordinary Shares, Epistem will have 9,748,240 ordinary shares of 1.5 pence each in issue.

For further details please contact:

 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

 

Peel Hunt LLP

James Steel +44 20 7418 8900

Oliver Jackson

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISUGUPWGUPCGQQ
Date   Source Headline
13th May 202010:26 amRNSHolding(s) in Company
12th May 20207:00 amRNSResults of Broker Option
7th May 20205:25 pmRNSHolding(s) in Company
7th May 20204:58 pmRNSPosting of shareholder circular
7th May 202011:05 amRNSSecond Price Monitoring Extn
7th May 202011:00 amRNSPrice Monitoring Extension
5th May 20206:24 pmRNSResult of Placing
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20208:50 amRNSProposed Placing and Broker Option
4th May 20205:00 pmRNSWHO Prequalification for Genedrive HCV-ID test
4th May 20202:05 pmRNSSecond Price Monitoring Extn
4th May 20202:00 pmRNSPrice Monitoring Extension
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:01 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSManufacturing milestones met for SARS-CoV-2 test
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20204:42 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20209:00 amRNSPrice Monitoring Extension
24th Apr 20203:30 pmRNSHolding(s) in Company
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
22nd Apr 20207:00 amRNSAppointment of Joint Broker
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20202:52 pmRNSHolding(s) in Company
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSCytiva collaboration on Coronavirus PCR Test
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:01 pmRNSPrice Monitoring Extension
16th Apr 20202:53 pmRNSHolding(s) in Company
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:06 amRNSSecond Price Monitoring Extn
14th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20207:01 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
31st Mar 202011:52 amRNSHolding(s) in Company
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20207:00 amRNSBusiness Update and SARS-COV-2 tests development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.